生物试剂
>
生化试剂
>
信号通路
> BMS-303141
加入收藏 取消收藏

BMS-303141  ≥98% (HPLC)

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：5mg 25mg 100mg in glass bottle
溶解性：溶于DMSO(20mg/mL)
产品描述：基本信息 产品编号： B10022 产品名称： BMS 303141 CAS: 943962-47-8   储存条件 粉末 2-8℃ 四年     分子式： C19H15Cl2NO4S 溶于液体 -80℃ 两年 分子量 424.30 -20℃ 一个月 化学名：  3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1′-biphenyl]-3-yl)-benzenesulfonamide Solubility (25°C)：   体外:   DMSO 85mg/mL(200.32mM) Ethanol Insoluble Water Insoluble 体内(现配现用): 1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility:2.5mg/mL(5.89mM);Suspended solution; Need ultrasonic 此⽅案可获得2.5mg/mL(5.89mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到400μL PEG300中，混合均匀；向上述体系中加⼊50μL Tween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:2.5mg/mL(5.89mM);Suspended solution; Need ultrasonic 此⽅案可获得2.5mg/mL(5.89mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。 3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:2.5mg/mL(5.89mM);Suspended solution; Need ultrasonic 此⽅案可获得2.5mg/mL(5.89mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL⽟⽶油中，混合均匀。 ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.3568mL 11.7841mL 23.5682mL 5mM 0.4714mL 2.3568mL 4.7136mL 10mM 0.2357mL 1.1784mL 2.3568mL 50mM 0.0471mL 0.2357mL 0.4714mL   生物活性 产品描述 一种强效的ATP柠檬酸裂合酶（ACL)抑制剂。 靶点 ACL (Cell-free assay) 0.13μM 体外研究 In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity 体内研究 Chronic oral dosing of BMS-303141 in high-fat fed mice lowers approximate 20-30% plasma cholesterol and triglycerides, as well as 30-50% fasting plasma glucose. Chronic treatment with BMS-303141 shows a gradual inhibition of weight gain along with a reduction in adiposity without apparent changes in food intake. BMS-303141 shows an oral bioavailability of 55% but a relatively short half-life of 2.1 h   推荐实验方法(仅供参考) Animal Administration Mice: Effect of BMS-303141 in high-fat fed mice is studied. There are a total of four groups in the study; mice on normal diet and high-fat diet controls, and two treated groups that are supplemented with BMS-303141 in their high-fat diet to an equivalent daily dose of 10 or 100 mg/kg. The study is continued for a total of 34 days. Food consumption and body weight gain are tracked along with weekly assessment of lipid and glucose plasma chemistries
保存条件：2-8℃

猜你喜欢